ConductScience.org, home

Paper18192510

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

Ataga KI and 11 others. Blood, 2008. Cited by 191 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Papers, record 18192510. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18192510

Download JSON
Disease
sickle cell disease163 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
PubMed
Journal
Blood
PubMed
Year
2008
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
191
iCite
Relative citation ratio, by iCite
4.67
iCite
Revised in PubMed
2026-05-18
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ataga KIKenneth I
2Smith WRWally R
3De Castro LMLaura M
4Swerdlow PPaul
5Saunthararajah YYogen
6Castro OOswaldo
7Vichinsky EElliot
8Kutlar AAbdullah
9Orringer EPEugene P
10Rigdon GCGreg C
11Stocker JWJonathan W
12ICA-17043-05 InvestigatorsGroup

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AcetamidesMajor topic
Anemia, Sickle CellMajor topic
Potassium Channel BlockersMajor topic
Triphenylmethyl CompoundsMajor topic
Adolescent
Adult
Female
Humans
Male
Middle Aged
Time Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00040677A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.ResultsYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in18434967Gardos pathway to sickle cell therapies?https://conductscience.org/library/papers/18434967

Source PubMed

Download CSV of comments and corrections

Cited by129

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 191 citations.

PMIDTitleJournalYearIn PapersSource
42979167Emerging and Repurposed Immune System Modulators for Alzheimer's Disease.Drug Des Devel Ther2026https://conductscience.org/library/papers/42979167PubMed
42547963Potassium Channels of the Airway Epithelium.Acta Physiol (Oxf)2026https://conductscience.org/library/papers/42547963PubMed
42279523
Senicapoc in Patients with Idiopathic Pulmonary Fibrosis or Other Progressive Fibrotic Interstitial Lung Diseases: Protocol for a Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Trial.
Diagnostics (Basel)2026https://conductscience.org/library/papers/42279523PubMed
42206270Sickle Cell Hepatic Vaso-Occlusive Crisis: A Case Report.Case Rep Hematol2026https://conductscience.org/library/papers/42206270PubMed
41981510SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol.BMC Cancer2026https://conductscience.org/library/papers/41981510PubMed
41827850The KCa3.1 K+ Channel and Cardiovascular Disease: An Upstream Target Linking Inflammation, Fibrosis and Electrical Instability.Cells2026https://conductscience.org/library/papers/41827850PubMed
41596371Hereditary Spherocytosis: Linking Ion Transport Defects to Osmotic Gradient Ektacytometry Profiles-A Review.Int J Mol Sci2026https://conductscience.org/library/papers/41596371PubMed
41531666MeMAGEN: A Phase IIa/IIb open-label trial of memantine testing safety and tolerability in sickle cell patients.Hemasphere2026https://conductscience.org/library/papers/41531666PubMed
41122971Kcnn4/KCa3.1 inhibition blunts polycystic kidney disease progression in mouse models.JCI Insight2025https://conductscience.org/library/papers/41122971PubMed
41059931Targeting PIEZO1-TMEM16F Coupling to Mitigate Sickle Cell Disease Complications.Am J Hematol2025https://conductscience.org/library/papers/41059931PubMed
41037639Enhanced PIEZO1 function contributes to the pathogenesis of sickle cell disease.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/41037639PubMed
40304011What interval of daily pain assessment is required to reliably diagnose chronic pain in SCD? The Pain in Sickle Cell Epidemiology Study.J Sick Cell Dis2024https://conductscience.org/library/papers/40304011PubMed
38650890Entry inhibitors as arenavirus antivirals.Front Microbiol2024https://conductscience.org/library/papers/38650890PubMed
38522095Successes and pitfalls in orphan drug development for sickle cell disease.Blood Adv2024https://conductscience.org/library/papers/38522095PubMed
38406513A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease.EJHaem2024https://conductscience.org/library/papers/38406513PubMed
38270470Exploring unconventional attributes of red blood cells and their potential applications in biomedicine.Protein Cell2024https://conductscience.org/library/papers/38270470PubMed
38136613Hypoxia, Ion Channels and Glioblastoma Malignancy.Biomolecules2023https://conductscience.org/library/papers/38136613PubMed
37890140The challenge of clinical end points in sickle cell disease.Blood2023https://conductscience.org/library/papers/37890140PubMed
37367787Role of Calcium-Activated Potassium Channels in Proliferation, Migration and Invasion of Human Chronic Myeloid Leukemia K562 Cells.Membranes (Basel)2023https://conductscience.org/library/papers/37367787PubMed
37125772The exocyst complex is required for the trafficking and delivery of KCa3.1 to the basolateral membrane of polarized epithelia.Am J Physiol Cell Physiol2023https://conductscience.org/library/papers/37125772PubMed

See all 129 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
SENICAPOCCHEMBL405821Results1https://conductscience.org/library/drugs/CHEMBL405821

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/18192510

GET https://conductscience.org/api/papers/v1/18192510/cited_by?page=2